Your browser is no longer supported. Please, upgrade your browser.
Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own36.76% Shs Outstand25.21M Perf Week-16.90%
Market Cap74.37M Forward P/E- EPS next Y-0.18 Insider Trans0.00% Shs Float16.09M Perf Month-37.23%
Income-28.80M PEG- EPS next Q-0.33 Inst Own29.20% Short Float3.68% Perf Quarter-42.16%
Sales- P/S- EPS this Y-39.00% Inst Trans23.63% Short Ratio1.60 Perf Half Y-45.87%
Book/sh0.71 P/B4.15 EPS next Y86.30% ROA-73.80% Target Price23.50 Perf Year-45.37%
Cash/sh1.26 P/C2.35 EPS next 5Y- ROE-127.60% 52W Range2.90 - 6.45 Perf YTD-47.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.26% Beta-
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low1.72% ATR0.39
Employees23 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)24.00 Volatility10.19% 8.00%
OptionableYes Debt/Eq0.60 EPS Q/Q27.50% Profit Margin- Rel Volume2.96 Prev Close2.95
ShortableYes LT Debt/Eq0.44 EarningsFeb 07 AMC Payout- Avg Volume369.76K Price2.95
Recom1.00 SMA20-37.96% SMA50-38.90% SMA200-39.03% Volume1,045,645 Change0.00%
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Jan-10-18 09:17AM  Heres Whats Moving Axsome Therapeutics and Pain Therapeutics Market Exclusive
08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-09-18 07:00AM  Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial GlobeNewswire -36.04%
Dec-19-17 07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire
Dec-14-17 07:00AM  Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation GlobeNewswire
Dec-06-17 07:00AM  Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering GlobeNewswire
Dec-01-17 07:00AM  Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -6.64%
Nov-28-17 07:00AM  Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine GlobeNewswire
Nov-08-17 09:59AM  Axsome reports 3Q loss Associated Press -5.15%
07:00AM  Axsome Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Sep-18-17 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-07-17 07:00AM  Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017 GlobeNewswire
Aug-09-17 10:25PM  Axsome reports 2Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-25-17 07:00AM  Axsome Therapeutics Announces AXS-06 (MoSEIC Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial GlobeNewswire
Jul-17-17 07:00AM  Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimers Disease Agitation GlobeNewswire
Jul-06-17 07:00AM  Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer GlobeNewswire
Jun-22-17 04:40AM  Will Axsome Therapeutics (AXSM) Continue to Surge Higher? Zacks
Jun-19-17 07:00AM  Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors GlobeNewswire +12.20%
May-09-17 09:55AM  Axsome reports 1Q loss Associated Press
08:15AM  Blog Coverage: Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease Accesswire
07:00AM  Axsome Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-08-17 07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimers Disease Agitation GlobeNewswire +7.69%
Mar-31-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.14%
Mar-30-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-29-17 07:00AM  Axsome Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-23-17 07:00AM  Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-21-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -18.18%
09:20AM  Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock GlobeNewswire
Mar-20-17 04:06PM  Axsome Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-14-17 07:02AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-11-17 01:04PM  AXSOME THERAPEUTICS, INC. Financials
Mar-07-17 05:56PM  Axsome reports 4Q loss Associated Press -9.18%
05:17PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:56PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:35PM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Feb-27-17 07:00AM  Axsome Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire +5.81%
Feb-14-17 05:24PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression GlobeNewswire
Feb-13-17 07:00AM  Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-10-17 07:01AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-07-17 07:00AM  Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Jan-12-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-04-17 05:14PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2017 GlobeNewswire
Jan-03-17 07:00AM  Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Nov-14-16 06:01PM  Axsome reports 3Q loss
05:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:30PM  Axsome Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
04:10PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-10-16 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
07:00AM  Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank GlobeNewswire
Oct-05-16 12:38PM  Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
Oct-04-16 07:00AM  Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome GlobeNewswire
Oct-03-16 11:12AM  Axsome Therapeutics: Teaching Old Drugs New Tricks
Sep-29-16 09:18AM  5 Stocks Under $10 Poised for Big Breakouts
Sep-19-16 07:00AM  Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference GlobeNewswire
Sep-06-16 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-02-16 05:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
04:47PM  Axsome Therapeutics Announces Transition of Chief Medical Officer GlobeNewswire
Aug-10-16 06:03AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Aug-09-16 06:53PM  Axsome reports 2Q loss
05:30PM  Axsome Therapeutics Reports Second Quarter 2016 Financial Results GlobeNewswire
04:33PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:21PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report
04:12PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual Report
Jul-13-16 07:01AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jul-12-16 04:41PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
Jul-05-16 07:00AM  Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference GlobeNewswire
Jun-27-16 07:00AM  Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes GlobeNewswire +7.75%
Jun-24-16 08:40AM  Axsome Therapeutics (AXSM) Catches Eye: Stock Jumps 6.6%
Jun-22-16 08:45AM  Can You Catch These 6 Stocks Under $10 on Their Way Up?
Jun-13-16 07:00AM  Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference GlobeNewswire -14.76%
Jun-10-16 04:08PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-11-16 05:20PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:48PM  Axsome reports 1Q loss
04:43PM  Axsome Therapeutics Reports First Quarter 2016 Financial Results GlobeNewswire
04:16PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
May-05-16 06:05AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-03-16 07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions GlobeNewswire -5.20%
Apr-21-16 04:42PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-20-16 07:00AM  Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimers Disease GlobeNewswire
Apr-08-16 08:26AM  Can the Uptrend Continue for Axsome Therapeutics (AXSM)?
Apr-04-16 07:00AM  Axsome Therapeutics to Present at the 15th Annual Needham Healthcare Conference GlobeNewswire
Mar-29-16 04:21PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
Mar-28-16 07:00AM  Axsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow Lesions GlobeNewswire
Mar-24-16 04:47PM  Axsome reports 4Q loss -6.18%
04:30PM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
04:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-22-16 05:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-17-16 07:00AM  Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression GlobeNewswire -16.56%
Mar-16-16 08:15AM  Axsome Therapeutics (AXSM) Jumps: Stock Rises 5.7% +5.39%
Mar-15-16 07:00AM  Axsome Therapeutics Receives New U.S. Patent Covering AXS-02 for the Treatment of Complex Regional Pain Syndrome GlobeNewswire +5.70%
Feb-22-16 10:20AM  Axsome Therapeutics, Inc. (Nasdaq: AXSM) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Feb-01-16 07:10AM  Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference at noodls
07:00AM  Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference GlobeNewswire
Jan-27-16 06:43AM  Axsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the Knee at noodls -17.43%
06:30AM  Axsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the Knee GlobeNewswire
Jan-04-16 06:30AM  Axsome Therapeutics to Present at Biotech Showcase 2016 GlobeNewswire
Nov-24-15 04:19PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
Developing an oral formulation of an existing therapy for pain and osteoarthritis.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JEFFS ROGERDirectorMar 29Option Exercise4.7342,538201,16346,912Mar 30 04:31 PM